Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma

Advances in Hodgkin lymphoma (HL) treatment have dramatically improved prognosis, with 5-year relative survival now over 80% in the United States (US) and Europe. However, subsequent malignancies, often occurring as late adverse effects of treatment, are a leading cause of morbidity and mortality

[1]  P. Hall,et al.  Stomach cancer risk after treatment for hodgkin lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Steven L Simon,et al.  Radiation dose to the esophagus from breast cancer radiation therapy, 1943-1996: an international population-based study of 414 patients. , 2013, International journal of radiation oncology, biology, physics.

[3]  P. Hall,et al.  Risk of treatment-related esophageal cancer among breast cancer survivors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Anthony J. Swerdlow,et al.  Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Greil,et al.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[6]  M. Charles.  Effects of Ionizing Radiation: United Nations Scientific Committee on the Effects of Atomic Radiation: UNSCEAR 2006 Report, Volume 1—Report to the General Assembly, with Scientific Annexes A and B , 2010 .

[7]  D. L. Preston,et al.  Solid Cancer Incidence in Atomic Bomb Survivors: 1958–1998 , 2007, Radiation research.

[8]  P. Hall,et al.  Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Marilyn Stovall,et al.  Dose Reconstruction for Therapeutic and Diagnostic Radiation Exposures: Use in Epidemiological Studies , 2006, Radiation research.

[10]  J. Fraumeni,et al.  Lung Cancer after Treatment for Hodgkin's Disease: Focus on Radiation Effects , 2003, Radiation research.

[11]  M. Stovall,et al.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  John D Boice,et al.  Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.

[13]  H. Storm,et al.  Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Hagenbeek,et al.  Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[16]  A Kreuger,et al.  Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Doll,et al.  Cancer mortality following X‐ray treatment for ankylosing spondylitis , 1994, International journal of cancer.

[18]  Konrad Donhuijsen.  Patterns of presentation of Hodgkin disease , 1993, Cancer.

[19]  L. Kalish,et al.  Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis , 1993, Cancer.

[20]  R. Holmes,et al.  Epidemiology and pathogenesis of esophageal cancer. , 2007, Seminars in radiation oncology.